Evidence map›Paper›PMID 42467728›Full record

ArticlePloS one2026

Inhibitory effect of 17β-estradiol on the THIK-1 channel.

Michihiro Tateyama, Yoshihiro Kubo

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michihiro TateyamaDivision of Biophysics & Neurobiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, Okazaki, Japan.ORCID https://orcid.org/0000-0002-1514-976X
Yoshihiro KuboDivision of Biophysics & Neurobiology, Department of Molecular and Cellular Physiology, National Institute for Physiological Sciences, Okazaki, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A two-pore domain K+ (K2P) channel, THIK-1, plays important roles in microglia and macrophage. THIK-1 is known to be activated by arachidonic acid and G protein-coupled receptors and inhibited by anesthetics. Steroids, such as cholesterol, estradiol and progesterone, are known to modulate several K+ channels and they might be potential modulators of THIK-1. We examined the effects of steroids on THIK-1 and found that estradiol inhibits mouse THIK-1 by approximately 40% (IC50 = 4.9 ± 1.5 μM). Docking simulations of THIK-1 with estradiol indicated possible docking sites, which were further assessed by introducing an alanine mutation into a residue at or near these locations. The F142A, V269A, and Y273A mutations reduced the inhibitory effect of estradiol. These residues are situated within the upper cavity above the Y gate in THIK-1 (pond), suggesting that the pond conformation is essential for estradiol-mediated inhibition. Conversely, the F145A and F276A mutations, located outside this region, were inhibited by 10 nM estradiol and enhanced inhibition by estradiol, estrone, estriol, and progesterone, likely due to conformational changes that facilitate steroid inhibition. The mouse T237S mutation, which corresponds to the reported human THIK-1 variant, produced effects similar to those seen with the F145A and F276A mutations, but to a lesser degree. In summary, estradiol-mediated THIK-1 inhibition depends on residues located in the pond, which may have physiological or pathological significance for THIK-1 variants which are inhibited by low concentration of estradiol.

Indexed as

EstradiolPotassium Channels, Tandem Pore DomainAnimalsHumansMiceMolecular Docking SimulationMutationProgesteroneEstradiolPotassium Channels, Tandem Pore DomainProgesterone

Identifiers

PMID42467728
PMCPMC13379078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.